Biodesix reports FY2024 revenue $71.3M (+45% YoY), exceeds guidance midpoint

BIODESIX INC

2024-FY EPS reported -$0.33 revenue$71,323,000

Total revenue $71.3M in FY2024, up 45% YoY; Q4 revenue $20.4M, up 39% YoY.
Lung Diagnostic revenue $64.7M (+43% YoY); test volumes 54,300 (+40% YoY).
Biopharma Services revenue $6.6M (+69% YoY); $12.2M contracted backlog for 2025 (+54%).
Cash and equivalents $26.2M as of Dec 31, 2024.
Results are preliminary and unaudited; Q4 and FY2024 figures subject to final audit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.